NVAX Novavax Inc Young James F (Director) Buy 100,000 1.91 191,000 09:03:41 2013-06-06
Glenn Gregory M (Chief Scientific Officer) Buy 1,000 2.01 2,009 09:12:18 2013-06-06
Glenn Gregory M (Chief Scientific Officer) Buy 1,000 1.83 1,830 09:12:18 2013-06-07
cjdbs... my bad. I'm sure you meant, "Young is COB" not CEO.
I was reading another post about Glenn, and thought you were referring to him.
A Homer Simpson moment... Doh!
Jeez.... I own more shares than Glenn. Now that's absurd!
Glad though that the Chairman of the Board is stepping up in a big way!
CMO... not CEO. Still VERY significant.
Senior Vice President, Chief Medical Officer
Gregory M. Glenn, M.D.
Dr. Glenn is a pioneer in vaccine delivery and adjuvants, and has brought several products from concept into clinical development, such as the travelers' diarrhea vaccine patch and an adjuvant patch for a pandemic influenza vaccine, developed under U.S. government contracts. He provided the scientific and technical leadership that led to the acquisition of IOMAI by Intercell in 2008. He has co-authored more than 150 research publications, scientific abstracts and presentations, and successful grant applications, and holds multiple U.S., European and other international patents. In addition, he is an associate editor of the journals Expert Review of Vaccines, and Human Vaccine, and was a board-certified pediatrician. Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.
I remember when they bought at 2.06/ 1.98 years ago only to watch the share value
plummet to 1.18 and stay there for eight months. LMFAO
Looking at a three chart,something interesting stands out...the right shoulder
of a bearish head and shoulders pattern is forming,hmmmmm
I don't think that buy would have been made if this was not going well...
_“Our activities with respect to our seasonal influenza vaccine candidate have been, and are, focused on identifying the manufacturing process to ensure consistent and enhanced immune responses in all strains.
Over the last six months we’ve made significant progress and expect to finalize our manufacturing process by mid-year 2013."